Paolo Ascierto, MD, of the National Tumor Institute Fondazione G. Pascale, Naples, Italy, discusses the safety of nivolumab for advanced melanoma in the context of the Phase II CheckMate 172 trial (NCT02156804). According to Prof. Ascierto, nivolumab has shown to be safe with few side effects. He further explains the impact of ipilimumab, the first checkpoint inhibitors and the toxicity associated with its use. However, he emphasizes that nivolumab is a more potent compound with less side effects with an incidence of immune-related grade 3/4 adverse events of around 5-6%. Recorded at the American Society of Oncology (ASCO) 2016 Annual Meeting held in Chicago, IL.
The safety of nivolumab for advanced melanoma
